Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-811 in Advanced Clear Cell Renal Cell Carcinoma
NCT07300241Phase 1Recruiting
- Sponsor
- Neomorph
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEO-811 in clear cell renal cell carcinoma (ccRCC), sponsored by Neomorph. Primary endpoints: Treatment Emergent Adverse Events and Maximum Tolerated Dose and/or Recommended Phase 2 Dose. Started Dec 2025; status: recruiting.
02
Drugs
NEO-811
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07300241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300241.